Adjuvant Osimertinib Improves OS in EGFR-Mutant, Early-Stage NSCLC
Adjuvant osimertinib can improve OS in patients with EGFR-mutated, early-stage non-small-cell lung cancer, the ADAURA trial suggests.
Stay updated with breaking news from Benjamin Solomon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adjuvant osimertinib can improve OS in patients with EGFR-mutated, early-stage non-small-cell lung cancer, the ADAURA trial suggests.
Adjuvant osimertinib can improve OS in patients with EGFR-mutated, early-stage non-small-cell lung cancer, the ADAURA trial suggests.
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifiraf...
Lifirafenib plus mirdametinib produced a tolerable safety profile and antitumor activity in patients with BRAF- or KRAS-mutant advanced or refractory solid tumors.
BeiGene, Ltd. , and SpringWorks Therapeutics, Inc. , today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in... | April 17, 2023